Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-amino-2-(4-bromophenyl)benzoxazole is a small molecule research compound belonging to the 2,5-disubstituted benzoxazole class of fused heterocyclic compounds. It has been studied in academic research as a DNA topoisomerase I inhibitor, demonstrating greater potency than the reference drug camptothecin in cell-free eukaryotic systems. Additionally, it has been investigated for its cytotoxic and antiapoptotic activities in breast cancer cell lines (such as MCF-7 and MDA-MB), where it has been shown to reduce VEGF activation, downregulate NF-κB and caspase-3 levels, and increase eNOS, Cytochrome C, and DNA damage (TUNEL). No formal clinical development program or commercial developer has been identified for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-amino-2-(4-bromophenyl)benzoxazole.